VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Immuno-genomic landscape of osteosarcoma.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
View in:
PubMed
subject areas
Acute-Phase Proteins
Aged
Antineoplastic Agents
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Disease-Free Survival
Female
Gene Amplification
Genes, erbB-1
Humans
Interleukin-9
Kaplan-Meier Estimate
Lipocalin-2
Lipocalins
Lung Neoplasms
Male
Middle Aged
Mutation
Piperidines
Proportional Hazards Models
Proto-Oncogene Proteins
Proto-Oncogene Proteins p21(ras)
Quinazolines
ras Proteins
TNF-Related Apoptosis-Inducing Ligand
authors with profiles
JIUN-KAE JACK LEE
HAI T TRAN
GEORGE R BLUMENSCHEIN
ANNE TSAO
IGNACIO IVAN WISTUBA
JOHN VICTOR HEYMACH
SUYU LIU